证券代码：301108 证券简称：洁雅股份 公告编号：2025-075 为进一步加强与投资者的互动交流，铜陵洁雅生物科技股份有限公司（以下 简称"公司"）将参加由安徽证监局指导、安徽上市公司协会与深圳市全景网络 有限公司联合举办的"2025 年安徽辖区上市公司投资者网上集体接待日"活动， 现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net），或关注微信公众号：全景财经，或下载全景路演 APP，参 与本次互动交流，活动时间为 2025 年 9 月 15 日（周一）15:00-17:00。届时公司 高管将在线就公司 2025 年半年度业绩、公司治理、发展战略、经营状况、融资 计划、股权激励和可持续发展等投资者关心的问题，与投资者进行沟通与交流， 欢迎广大投资者踊跃参与！ 特此公告。 铜陵洁雅生物科技股份有限公司董事会 2025 年 9 月 8 日 铜陵洁雅生物科技股份有限公司 关于参加 2025 年安徽辖区上市公司投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏 ...

Market Overview - The personal care products sector rose by 2.89% on September 4, with Jieya Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3765.88, down 1.25%, while the Shenzhen Component Index closed at 12118.7, down 2.83% [1] Stock Performance - Jieya Co., Ltd. (301108) closed at 34.40, up 13.16% with a trading volume of 72,700 shares and a turnover of 243 million yuan [1] - Yiyi Co., Ltd. (001206) closed at 26.72, up 10.00% with a trading volume of 131,800 shares and a turnover of 342 million yuan [1] - Dengkang Oral Care (001328) closed at 43.55, up 7.40% with a trading volume of 53,000 shares and a turnover of 226 million yuan [1] - Other notable performers include Ziya Co., Ltd. (003006) up 5.13%, and Liangmian Needle (600249) up 3.29% [1] Capital Flow - The personal care products sector saw a net inflow of 56.24 million yuan from institutional investors, while retail investors experienced a net outflow of 6.89 million yuan [2] - The main capital inflow was observed in Yiyi Co., Ltd. with 64.76 million yuan, while the largest outflow was from Jieya Co., Ltd. with 22.08 million yuan [3] Individual Stock Analysis - Jieya Co., Ltd. had a main capital inflow of 3.69 million yuan, but retail investors showed a net outflow of 22.07 million yuan [3] - Dengkang Oral Care experienced a net outflow of 4.13 million yuan from main capital, while retail investors had a net inflow of 14.52 million yuan [3] - Ziya Co., Ltd. had a net inflow of 3.36 million yuan from main capital, with a slight outflow from retail investors [3]

Group 1 - Pacific Securities (601099) experienced a significant surge, hitting the daily limit up, with other securities firms like Huayin Securities (002945), Guosheng Jinkong (002670), and Xinda Securities (601059) also rising [1] - Huatai Securities' research report indicated that since the beginning of the year, the equity market has been on an upward trend, but the brokerage index has not recovered as much as the broader market, with large brokerages still valued at historically low levels [3] - The report highlighted that the current yield on equity assets is steadily increasing, with stock trading volumes and margin financing continuing to break through, indicating a strong recovery phase for brokerage operations [3] Group 2 - In addition to the securities sector, bank stocks also showed strength, with Agricultural Bank rising over 2% and Postal Savings Bank (601658) increasing by over 1% [4] - The pet economy concept stocks surged in the afternoon, with Yiyi Co. (001206) hitting the daily limit up, and other companies like Jieya Co. (301108) and Tianyuan Pet (301335) rising over 10% [4] - Renewable energy sectors such as photovoltaic and energy storage continued to perform well, with Shangneng Electric (300827) reaching a 20% limit up, and companies like JinkoSolar (002459) also hitting the daily limit [4]

Group 1 - The pet economy concept stocks in the A-share market experienced significant gains, with Jieya Co., Ltd. rising over 10% [1] - Yiyi Co., Ltd. hit the daily limit with a 10% increase [1] - Tianyuan Pet increased by over 9%, while Lusi Co., Ltd. rose over 8% [1] Group 2 - Peti Co., Ltd. saw an increase of over 7%, and Chuangyuan Co., Ltd. rose over 6% [1] - Guai Bao Pet and Suo Bao Protein both increased by over 5% [1] - Zhongchong Co., Ltd. and Yuanfei Pet both rose over 4% [1]

Group 1 - The pet economy concept stocks experienced a significant afternoon surge, with Yi Yi Co., Ltd. hitting the daily limit up [1] - Jie Ya Co., Ltd. and Tian Yuan Pet both rose over 10%, indicating strong market interest in the pet industry [1] - Other companies such as Chuang Yuan Co., Ltd., Yi Zhi Mo Yu, Lu Si Co., Ltd., Pei Ti Co., Ltd., and Qu Dong Li also saw increases, reflecting a broader trend in the sector [1]

铜陵洁雅生物科技股份有限公司 董事会审计委员会关于会计政策变更的审核意见 铜陵洁雅生物科技股份有限公司（以下简称"公司"）董事会审计委员会（以 下简称"审计委员会"）根据《中华人民共和国公司法》《中华人民共和国证券 法》《深圳证券交易所创业板股票上市规则》《公司章程》以及《董事会审计委 员会实施细则》的有关规定，本着勤勉尽责的原则，对公司会计政策变更事项进 行了认真的审阅与核查。经全体委员充分讨论后，发表审核意见如下： 为了提高原材料、周转材料成本核算与 SAP 信息管理系统的适配性，结合 公司实际情况和历年成本核算经验，公司拟自 2025 年 7 月 1 日起将原材料、周 转材料发出的计价方法由"月末一次加权平均法"变更为"移动加权平均法"。 本次变更采用未来适用法处理，无需对已披露的财务报表进行追溯调整，不会对 公司以往各期间的财务状况、经营成果和现金流量产生影响。 公司 2024 年 1 月至 2025 年 6 月的原材料采购价格波动较小，经公司财务部 估算，将原材料计价方法由月末一次加权平均法变更为移动加权平均法，对往期 净利润的影响不超过 2%、净资产的影响不超过 0.02%。 综上所述，本次会计政 ...

Core Viewpoint - The company, Jieya Co., announced the approval of a proposal to grant restricted stock to incentive targets during the fourth meeting of its sixth board of directors [2] Group 1 - The board meeting was held on the evening of September 2 [2] - The proposal aims to incentivize specific targets within the company through the issuance of restricted stock [2]

Core Viewpoint - The legal opinion letter from Anhui Tianhe Law Firm confirms that Tongling Jieya Biotechnology Co., Ltd. has complied with relevant laws and regulations regarding its 2025 Restricted Stock Incentive Plan, including necessary approvals and authorizations for the initial grant of restricted stock [1][3][4]. Summary by Sections Approval and Authorization of Grant - The Compensation and Assessment Committee and the Board of Directors have approved the draft of the 2025 Restricted Stock Incentive Plan and related proposals [3][4]. - The company has fulfilled necessary approval and authorization procedures for the grant of restricted stock [4][5]. Basic Information of the Grant - The initial grant date for the restricted stock is set for September 2, 2025, with a total of 1,498,000 shares to be granted to 10 incentive recipients [4][5]. - The grant date complies with the regulations, being within 60 days of the shareholders' meeting approval [5]. Recipients of the Grant - The distribution of the granted shares among the recipients is as follows: - Directors and senior management will receive 38.46% of the total shares, while other incentivized personnel will receive 43.85% [6]. - The total number of shares granted to the 10 recipients is 1,498,000, with a reserved portion of 322,000 shares [6]. Conditions for Granting - Recipients must meet specific conditions to be eligible for the restricted stock, including no negative audit opinions in the last fiscal year and no legal restrictions on participating in stock incentives [7][8]. - The company has confirmed that all conditions for granting the restricted stock have been met [8]. Conclusion - The legal opinion concludes that all necessary approvals, grant dates, recipient qualifications, and conditions have been satisfied, ensuring compliance with the relevant regulations [8].

Core Viewpoint - The company has approved the first grant of restricted stock under its 2025 Restricted Stock Incentive Plan, granting 1,498,000 shares at a price of 12.63 yuan per share to 10 eligible recipients, with the grant date set for September 2, 2025 [1][10][14]. Summary by Sections Incentive Plan Overview - The 2025 Restricted Stock Incentive Plan aims to motivate directors, senior management, and other key personnel deemed necessary for incentivization [1][4]. - The total number of shares granted is 1,498,000, which represents 82.31% of the total incentive plan [3][11]. Grant Details - The grant includes 1,498,000 shares to 10 recipients, with 700,000 shares allocated to directors and senior management, and 798,000 shares to other incentivized personnel [3][11]. - A reserve of 322,000 shares (17.69% of the total) is set aside for future grants [3][11]. Vesting Conditions - The vesting of the restricted stock is contingent upon meeting specific performance targets over three years, with annual assessments [6][7]. - The performance targets are set as follows: - 2025: Revenue growth of at least 25% compared to 2024 - 2026: Revenue growth of at least 50% compared to 2024 - 2027: Revenue growth of at least 100% compared to 2024 [6][7]. Approval Process - The plan has undergone necessary approvals, including reviews by the Compensation and Assessment Committee and the Board of Directors [9][10]. - The company has confirmed that all grant conditions have been met, ensuring compliance with relevant regulations [10][14]. Financial Impact - The fair value of the restricted stock will be calculated using the Black-Scholes model, and the associated costs will be recognized over the vesting period [11][12]. - The estimated total expense for the first grant will impact the company's net profit across the years 2025 to 2028 [12]. Compliance and Legal Review - A legal opinion confirms that the grant complies with all applicable laws and regulations, and the eligibility of the recipients has been verified [14][15].

Group 1 - The incentive plan involves the allocation of restricted stocks among various incentive recipients, with a total of 182,000 shares granted, representing 1.62% of the company's total share capital [1] - The distribution of granted rights includes 70,000 shares (38.46%) for directors and senior management, and 79,800 shares (43.85%) for other personnel deemed necessary for motivation [1] - A reserved portion of 32,200 shares (17.69%) is also included in the incentive plan, bringing the total granted rights to 182,000 shares [1] Group 2 - The company will disclose relevant information about the incentive recipients in a timely and accurate manner after receiving clear opinions from the Compensation and Assessment Committee and legal counsel [2] - The list of other personnel deemed necessary for motivation by the board of directors is also mentioned, indicating a structured approach to employee incentives [2]